Retrospective Cohort Study
Copyright ©The Author(s) 2015.
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 235-242
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.235
Table 1 Differences in Kaplan-Meier estimated median survival between individual drugs groups
Drug nameNumber taking the drug out of 164 patientsMedian survival estimate for those taking the drug (d)Median survival for those not taking the drug (d)P value (log rank test)
ACEI/ARB415396110.652
CCB268155280.061
Aspirin555045460.846
Statins395045770.368
Table 2 Univariate and multivariate cox regression comparing individual drug groups with those not taking the drug
Drug nameNumber taking the drug out of 164 patientsUnivariate analysis
Multivariate analysis
HR (95%CI)P-valueHR (95%CI)P-value
ACEI/ARB411.094 (0.741-1.614)0.6531.129 (0.617-2.065)0.693
CCB260.635 (0.393-1.025)0.0630.475 (0.250-0.902)0.023
Aspirin551.036 (0.726-1.479)0.8461.041 (0.651-1.667)0.865
Statins391.200 (0.806-1.787)0.3691.055 (0.614-1.814)0.845
Table 3 Kaplan-Meier survival estimates and multivariate cox regression comparing patients taking a combination of medications with patients on one or neither drug
Drug combinationNumber of people onKaplan-Meier estimated median survival
Multivariate cox regression
combination out of 164For those on the drug combinationFor those not on drug combinationP-value (log rank)HR (95%CI)P-value
CCB + aspirin1514145280.0120.300 (0.122-0.735)0.008
CCB + statin125445390.2840.413 (0.155-1.101)0.077
CCB + ACEI/ARB124855410.4500.512 (0.194-1.348)0.175
Aspirin + statin275045460.6970.969 (0.509-1.844)0.924
Aspirin + ACEI/ARB224855690.9230.948 (0.438-2.054)0.893
Statin + ACEI/ARB213685770.4261.126 (0.533-2.379)0.756
Table 4 Comparison of differences in prognostic indicators between drug groups
CharacteristicsNo CCB/aspirin, n (%)CCB and aspirin, n (%)Aspirin without CCB, n (%)CCB without Aspirin, n (%)P value
n = 98n = 15n = 40n = 11
Sex
Male56 (57.1)5 (33.3)25 (62.5)8 (72.7)0.169
Age (yr)
< 6039 (39.8)5 (33.3)8 (20.0)3 (27.3)0.157
≥ 6059 (60.2)10 (66.7)32 (80.0)8 (72.7)
Blood pressure status
Hypertensive27 (27.6)13 (86.7)22 (55.0)11 (100.0)0.000
Non-hypertensive71 (72.4)2 (13.3)18 (45.0)0 (0.0)
BMI
< 18.52 (2.0)0 (0)1 (2.5)0 (0.0)0.307
18.5-2552 (53.1)5 (33.3)24 (60.0)3 (27.3)
> 2541 (41.8)9 (60.0)14 (35.0)8 (72.7)
Adjuvant chemotherapy
Received post-op69 (70.4)9 (60.0)23 (57.5)9 (81.8)0.333
Not received24 (24.5)5 (33.3)13 (32.5)1 (9.1)
CA19-9
< 4727 (27.6)3 (20.0)9 (22.5)1 (9.1)0.437
47-100051 (52.0)7 (46.7)20 (50.0)7 (63.6)
> 10008 (8.2)3 (20.0)6 (15.0)3 (27.3)
ASA grade
1-281 (82.7)12 (80.0)22 (55.0)8 (72.7)0.008
3-417 (17.3)3 (20.0)18 (45.0)3 (27.3)
Resection value
R014 (14.3)6 (40.0)9 (22.5)5 (45.5)0.020
R183 (84.7)9 (60.0)31 (77.5)6 (54.5)
T status
T1-23 (3.1)2 (13.3)1 (2.5)0 (0.0)0.199
T3-495 (96.9)13 (86.7)39 (97.5)11 (100.0)
N status
N07 (7.1)3 (20.0)5 (12.5)0 (0.0)0.242
N190 (91.8)12 (80)35 (87.5)11 (100.0)
Table 5 Kaplan-Meier survival estimates and multivariate cox regression comparing patients taking a combination of calcium channel blockers + aspirin with patients on one or neither drug
Drug groupNumber of peopleEstimated medianP-value (log rank)Multivariate cox regression
in groupsurvival (d)compared to controlHR (95%CI)P-value
Control (no CCB/aspirin)98601-1-
CCB + aspirin1514140.0290.332 (0.126-0.870)0.025
Aspirin without CCB403920.0321.658 (0.968-2.840)0.066
CCB without Aspirin113430.5631.039 (0.416-2.595)0.935